- Moderna and Merck announce promising results in trials of melanoma vaccine https://english.elpais.com/science-tech/2022-12-14/moderna-and-merck-announce-promising-results-in-trials-of-melanoma-vaccine.html 2 comments science
Linking pages
- An experimental vaccine increases survival rates by up to 50% in four people with highly-aggressive brain cancer | Health | EL PAÍS English https://english.elpais.com/health/2024-05-02/an-experimental-vaccine-increases-survival-rates-by-up-to-50-in-four-people-with-highly-aggressive-brain-cancer.html 11 comments
- Two synthetic biology experiments offer hope for future cancer treatments | Science & Tech | EL PAÍS English Edition https://english.elpais.com/science-tech/2022-12-16/two-synthetic-biology-experiments-offer-hope-for-future-cancer-treatments.html 6 comments
Linked pages
- Covid-19 in Spain: The differences between the Pfizer, Moderna and Oxford coronavirus vaccines: what we know so far | Science & Tech | EL PAÍS English Edition https://english.elpais.com/science_tech/2020-12-01/the-differences-between-the-pfizer-moderna-and-oxford-coronavirus-vaccines-what-we-know-so-far.html 15 comments
- Science in EL PAÍS English https://english.elpais.com/science-tech/ 6 comments
- Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx 5 comments
Related searches:
Search whole site: site:english.elpais.com
Search title: Cancer: Moderna and Merck announce promising results in trials of melanoma vaccine | Science & Tech | EL PAÍS English Edition
See how to search.